Fabrication of new hybrid scaffolds for in vivo perivascular application to treat limb ischemia.

Research output: Contribution to journalArticle (Academic Journal)

Abstract

Cell therapies are emerging as a new therapeutic frontier for the treatment of ischemic disease. However, femoral occlusions can
be challenging environments for effective therapeutic cell delivery. In this study, cell-engineered hybrid scaffolds are implanted
around the occluded femoral artery and the therapeutic benefit through the formation of new collateral arteries is investigated.
First, it is reported the fabrication of different hybrid “hard‐soft” 3D channel‐shaped scaffolds comprising either poly(ε‐
caprolactone) [PCL] or polylactic-co-glycolic acid [PLGA]) and electro-spun of gelatin (GL) nanofibers. Both PCL-GL and PLGA-GL
scaffolds show anisotropic characteristics in mechanical tests and PLGA displays a greater rigidity and faster degradability in wet
conditions. The resulting constructs are engineered using human adventitial pericytes (APCs) and both exhibit excellent
biocompatibility. The 3D environment also induces expressional changes in APCs, conferring a more pronounced proangiogenic
secretory profile. Bioprinting of alginate-pluronic gel (AG/PL), containing APCs and endothelial cells, completes the hybrid scaffold
providing accurate spatial organization of the delivered cells. The scaffolds implantation around the mice occluded femoral artery
shows that bioengineered PLGA hybrid scaffold outperforms the PCL counterpart accelerating limb blood flow recovery through
the formation arterioles with diameters greater than 50 μm, demonstrating the therapeutic potential in stimulating reparative
angiogenesis.
Original languageEnglish
JournalFrontiers in Cardiovascular Medicine
Publication statusSubmitted - 24 Aug 2020

Fingerprint Dive into the research topics of 'Fabrication of new hybrid scaffolds for in vivo perivascular application to treat limb ischemia.'. Together they form a unique fingerprint.

Cite this